Stocks · News reference

Innate Pharma shares are trading higher after the company announced it has entered into a strategic partnership with Swedish Orphan Biovitrum AB to enable initiation of the TELLOMAK-3 confirmatory Phase 3 study in cutaneous T-cell lymphoma.

Aug 10, 2026, 2:40 PMBenzinga Newsdesk

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

Fiscal.aiOct 27, 2026, 8:02 AM
Innate Pharma Announces Updated Timing for PACIFIC-9 Phase 3 Trial Data Readout
Innate Pharma reported that AstraZeneca has adjusted the expected timeline for the high-level data readout of the Phase 3 PACIFIC-9 clinical trial to the first half of 2027.
IPHA
BenzingaSep 17, 2026, 3:51 PMBenzinga Newsdesk
BTIG Reiterates Buy on Innate Pharma, Maintains $9 Price Target
BTIG analyst Jeet Mukherjee reiterates Innate Pharma (NASDAQ:IPHA) with a Buy and maintains $9 price target.
IPHA
BenzingaSep 17, 2026, 12:27 PMBenzinga Insights
Innate Pharma H1 2026 Earnings Call Transcript
Innate Pharma (NASDAQ:IPHA) held its quarterly earnings conference call on Thursday. Below is the complete transcript from the call. This content is powered by Benzinga APIs. For comprehensive financial data and
IPHA
BenzingaSep 17, 2026, 11:11 AMBenzinga Insights
Earnings Scheduled For September 17, 2026
Companies Reporting Before The Bell • 111 (NASDAQ:YI) is projected to report earnings for its second quarter. • Innate Pharma (NASDAQ:IPHA) is projected to report quarterly loss at $0.16 per share on revenue of $9.10
IPHA UPXI YI